{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:22:59Z","timestamp":1777418579845,"version":"3.51.4"},"reference-count":33,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[1998,2,1]],"date-time":"1998-02-01T00:00:00Z","timestamp":886291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[1998,2]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To review the clinical pharmacology of fosfomycin tromethamine, a new antimicrobial agent for the treatment of uncomplicated lower urinary tract infections (UTIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCE:<\/jats:title>\n                    <jats:p>Publications in English on fosfomycin, fosfomycin tromethamine, and fosfomycin trometamol (MEDLINE, 1970\u20131997), as well as unpublished studies submitted to the Food and Drug Administration (FDA), were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION:<\/jats:title>\n                    <jats:p>Comparative, randomized, controlled studies were used to analyze the efficacy and safety of fosfomycin tromethamine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS:<\/jats:title>\n                    <jats:p>Fosfomycin tromethamine is an oral antimicrobial indicated for the treatment of uncomplicated lower UTIs. This agent is active in the urine against common uropathogens that are associated with cystitis in women, including organisms resistant to other antibiotics. A single dose of fosfomycin tromethamine is well absorbed and produces therapeutic concentrations in the urine for 2\u20134 days. Comparative clinical trials suggest that a single dose of fosfomycin tromethamine 3.0 g is as clinically effective as 7- to 10-day treatment regimens of standard agents used to treat UTIs, such as nitrofurantoin, norfloxacin, and trimethoprim\/sulfamethoxazole. Fosfomycin tromethamine is well tolerated and appears safe to use during pregnancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Fosfomycin tromethamine is the only antimicrobial to be approved by the FDA for single-dose therapy in women with acute cystitis. It is as effective and safe as multidose comparators and appears safe to use during pregnancy. The acquisition cost of this new drug will need to be weighed against the improved compliance and convenience associated with its use in the treatment of uncomplicated UTIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJETIVO:<\/jats:title>\n                    <jats:p>Revisar la farmacolog\u00eda de la fosfomicina trometamina, un agente antimicrobiano nuevo indicado para el tratamiento de las infecciones leves del tracto urinario.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>FUENTES DE INFORMACI\u00d3N:<\/jats:title>\n                    <jats:p>Publicaciones en ingl\u00e9s sobre la fosfomicina, fosfomicina trometamina, y fosfomicina trometamol identificadas a trav\u00e9s de MEDLINE. Adem\u00e1s, estudios sin publicar suministrados a la Administraci\u00f3n de Drogas y Alimentos de los Estados Unidos.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SELECCI\u00d3N DE FUENTES DE INFORMACI\u00d3N:<\/jats:title>\n                    <jats:p>Estudios comparativos, controlados, y de asignaci\u00f3n aleatoria del tratamiento de prueba, empleados para analizar la eficacia, y la seguridad de la fosfomicina trometamina.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>S\u00cdNTESIS:<\/jats:title>\n                    <jats:p>La fosfomicina trometamina es un agente antimicrobiano oral indicado para el tratamiento de las infecciones leves del tracto urinario. Este agente es activo en la orina contra uropat\u00f3genos que est\u00e1n asociados con la cistitis en la mujer, incluyendo organismos resistentes a otros antibi\u00f3ticos. Una dosis linica de la fosfomicina trometamina se absorbe bi\u00e9n y produce concentracions terap\u00e9uticas en la orina for un per\u00edodo de 2\u20134 d\u00edas. Estudios cl\u00ednicos comparativos sugieren que una dosis \u00fanica de 3.0 g de fosfomicina trometamina es tan efectiva cl\u00ednicamente como un r\u00e9gimen de tratamiento de 7\u201310 d\u00edas con agentes com\u00fanmente usados en esta condici\u00f3n tales como la nitrofuranto\u00edna, la norfloxacina, y el sulfametoxazol con trimetoprim. La fosfomicina trometamina se tolera bi\u00e9n y no parecer ocasionar efectos adversos durante el embarazo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONES:<\/jats:title>\n                    <jats:p>La fosfomicina trometamina es el \u00fanico agente antimicrobiano a ser aprobado por la Administraci\u00f3n de Drogas y Alimentos de los Estados Unidos como terapia de dosis \u00fanica en mujeres con cistitis aguda. Este agente es tan efectivo y seguro como los agentes competidores usados en dosis m\u00faltiples. Adem\u00e1s, su uso durante el embarazo parece seguro. El costo elevado de adquisici\u00f3n de este nuevo medicamento debe pesarse contra sus ventajas sobretodo en lo referente la mejoramiento del cumplimiento del tratamiento y conveniencia de administraci\u00f3n en pacientes con infecciones leves del tracto urinario.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIF:<\/jats:title>\n                    <jats:p>Revoir la pharmacologie clinique du trom\u00e9thamine de fosfomycine, un nouvel agent antimicrobien pour le traitement des infections urinaires basses non compliqu\u00e9es.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>REVUE DE LITT\u00c9RATURE:<\/jats:title>\n                    <jats:p>Les publications en langue anglaise sur la fosfomycine, le trom\u00e9thamine de fosfomycine, et le trom\u00e9tamol de fosfomycine ont \u00e9t\u00e9 recherch\u00e9es dans la banque informatis\u00e9e MEDLINE aussi bien que les \u00e9tudes non publi\u00e9es soumises \u00e0 l'Administration des Drogues et Alimentaires (ADA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>S\u00c9LECTION DES \u00c9TUDES:<\/jats:title>\n                    <jats:p>Les \u00e9tudes comparatives, randomis\u00e9es, et contr\u00f4l\u00e9es ont \u00e9t\u00e9 retenues pour analyser l'efficacit\u00e9 et l'innocuit\u00e9 du trom\u00e9thamine de fosfomycine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>R\u00c9SUM\u00c9:<\/jats:title>\n                    <jats:p>Le trom\u00e9thamine de fosfomycine est un antibiotique oral indiqu\u00e9 pour le traitement des infections urinaires basses non compliqu\u00e9es. Cet agent est actif dans l'urine contre les pathog\u00e8nes du tractus urinaire responsables de la cystite chez la femme, incluant des organismes r\u00e9sistants \u00e0 d'autres antibiotiques. Une dose unique de trom\u00e9thamine de fosfomycine est bien absorb\u00e9e et produit des concentrations th\u00e9rapeutiques dans l'urine pour une p\u00e9riode de 2\u20134 jours. Des essais cliniques comparatifs sugg\u00e8rent qu'une dose unique de 3 g de trom\u00e9thamine de fosfomycine est aussi efficace cliniquement qu'un traitement standard de 7\u201310 jours avec les agents habituellement utilis\u00e9s pour le traitement des infections urinaires basses, comme la nitrofuranto\u00efne, la norfloxacine, et le trim\u00e9thoprime-sulfam\u00e9thoxazole. Le trom\u00e9thamine de fosfomycine est bien tol\u00e9r\u00e9 et semble s\u00e9curitaire lors de grossesse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Le trom\u00e9thamine de fosfomycine est le seul antibiotique approuv\u00e9 par la ADA pour la th\u00e9rapie unidose de la cystite aigu\u00eb chez la femme. Il est aussi efficace et s\u00e9curitaire que les agents comparateurs \u00e0 doses multiples et semble s\u00e9curitaire lors de grossesse. Le co\u00fbt d'acquisition de ce nouveau m\u00e9dicament peut se justifier par une meilleur observance du traitement et la facilit\u00e9 associ\u00e9e \u00e0 son emploi lors de traitement des infections urinaires basses non compliqu\u00e9es.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.17227","type":"journal-article","created":{"date-parts":[[2004,3,11]],"date-time":"2004-03-11T17:08:19Z","timestamp":1079024899000},"page":"215-219","source":"Crossref","is-referenced-by-count":34,"title":["Single-Dose Treatment of Acute Cystitis with Fosfomycin Tromethamine"],"prefix":"10.1177","volume":"32","author":[{"given":"Gary E","family":"Stein","sequence":"first","affiliation":[{"name":"Gary E Stein PharmD, Associate Professor of Medicine and Pharmacology, Department of Medicine, Michigan State University, B-320 Life Sciences Bldg., E. Lansing, MI 48824, FAX 517\/353-1922"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1998,2,1]]},"reference":[{"key":"bibr1-aph.17227","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1974.tb43277.x"},{"key":"bibr2-aph.17227","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.6.1235"},{"key":"bibr3-aph.17227","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/35.1.228"},{"key":"bibr4-aph.17227","doi-asserted-by":"publisher","DOI":"10.1159\/000414982"},{"key":"bibr5-aph.17227","doi-asserted-by":"publisher","DOI":"10.1128\/JB.113.2.895-900.1973"},{"key":"bibr6-aph.17227","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.5.844"},{"key":"bibr7-aph.17227","doi-asserted-by":"publisher","DOI":"10.1159\/000414966"},{"key":"bibr8-aph.17227","doi-asserted-by":"publisher","DOI":"10.1007\/BF01645261"},{"key":"bibr9-aph.17227","doi-asserted-by":"publisher","DOI":"10.1007\/BF01710019"},{"key":"bibr10-aph.17227","doi-asserted-by":"publisher","DOI":"10.1007\/BF01643430"},{"key":"bibr11-aph.17227","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/34.6.853"},{"key":"bibr12-aph.17227","first-page":"55","volume":"6","author":"Bergan T","year":"1995","journal-title":"Rev Contemp Pharmacother"},{"key":"bibr13-aph.17227","doi-asserted-by":"publisher","DOI":"10.1159\/000222044"},{"key":"bibr14-aph.17227","doi-asserted-by":"publisher","DOI":"10.1159\/000414969"},{"key":"bibr15-aph.17227","doi-asserted-by":"publisher","DOI":"10.1159\/000222040"},{"key":"bibr16-aph.17227","doi-asserted-by":"publisher","DOI":"10.1159\/000414976"},{"key":"bibr17-aph.17227","doi-asserted-by":"publisher","DOI":"10.1159\/000472875"},{"key":"bibr18-aph.17227","first-page":"411","volume":"27","author":"Borgia M","year":"1989","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"bibr19-aph.17227","volume-title":"Package insert. Monurol (fosfomycin tromethamine)","year":"1997"},{"key":"bibr20-aph.17227","doi-asserted-by":"publisher","DOI":"10.1159\/000414970"},{"key":"bibr21-aph.17227","first-page":"71","volume":"6","author":"Reeves DS","year":"1995","journal-title":"Rev Contemp Pharmacother"},{"key":"bibr22-aph.17227","doi-asserted-by":"publisher","DOI":"10.1007\/BF01643433"},{"key":"bibr23-aph.17227","doi-asserted-by":"publisher","DOI":"10.1007\/BF01871127"},{"key":"bibr24-aph.17227","doi-asserted-by":"publisher","DOI":"10.1159\/000238813"},{"key":"bibr25-aph.17227","doi-asserted-by":"publisher","DOI":"10.1159\/000238814"},{"key":"bibr26-aph.17227","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.11.2612"},{"key":"bibr27-aph.17227","doi-asserted-by":"publisher","DOI":"10.1159\/000238817"},{"key":"bibr28-aph.17227","doi-asserted-by":"publisher","DOI":"10.1159\/000414993"},{"key":"bibr29-aph.17227","doi-asserted-by":"publisher","DOI":"10.1007\/BF01710021"},{"key":"bibr30-aph.17227","first-page":"63","volume":"6","author":"Naber KG","year":"1995","journal-title":"Rev Contemp Pharmacother"},{"key":"bibr31-aph.17227","doi-asserted-by":"publisher","DOI":"10.1007\/BF01710022"},{"key":"bibr32-aph.17227","unstructured":"Medical Economics, 1997. Montvale, NJ."},{"key":"bibr33-aph.17227","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199603283341306"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.17227","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.17227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:07:03Z","timestamp":1777374423000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.17227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1998,2]]}},"alternative-id":["10.1345\/aph.17227"],"URL":"https:\/\/doi.org\/10.1345\/aph.17227","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,2]]}}}